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The disparity between at-risk pregnancies and the frequency of
disease presentation in HPA-1a NAIT is usually due to an HLA linked
inability to make an effective antibody response
Using molecular modeling the antigen presentation of HPA-1a allele
seems to be implicated in the HLA linked response to make antibody in
standard serologic methods
Sensitive SPR data demonstrates that HPA-1a alloimmunization still
occurs in HPA-1a at risk patients despite being HLA-DRB3 negative
A monoclonal antibody that blocks HPA-1a binding (not shown) is
under development in the UK to ameliorate HPA-1a mediated NAIT.
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